BLOG
Hospitals poised for strong earnings show in Q4


Combined revenues of 5 pan-India hospitals put together de-grew 4% QoQ to ₹6116 crore (14% growth YoY) whereas EBITDA de-grew by 9% QoQ to ~₹ 1338 crore (15% growth YoY). Q3 is typically a soft quarter being a festive quarter and most of the elective surgeries get postponed. However, the YoY growth tempo was maintained.
Quarterly gyrations notwithstanding, we continue to like hospitals space as a theme of healthcare premiumization as companies continue to invest in productive beds
.
Improving payor-mix (more private insurance covered patients and lower government scheme patients) has helped the companies to generate better ARPOB. The proportion of private insurance covered patients has gone up from 15% to ~40% in four years at the expense of government scheme patients (37% to 14%).
Similarly, better case-mix (higher number of critical surgeries such as organ transplants, complex cardiovascular surgeries, cancer treatments etc.) has helped the companies to generate better ARPOB as well as margins. Complex surgeries and procedures now account for ~15% of the overall procedures for these players as against ~10% last year.
Most of the new hospital assets inducted in the last 5-7 years are turning profitable, boosting the combined average ROCE which is now trending at 19% as against 9% in FY20.
With very less balance sheet stress and comfortable leverage position, these companies are entering into a new capex phase (+7000 beds additions over the next 2-3 years) which is a good 40% expansion over the existing capacity.
Healthcare growth trend stands out in a volatile environment impacted by tariff related uncertainties and earnings slowdown across sectors.
Top Picks- Narayana Hrudayalaya – TP- ₹1600; HCG – TP- ₹620 ; Apollo Hospital – TP – ₹7270
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Related content
Blogs
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Video

Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.

Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.

Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Podcasts


